Sharon Stevenson

Sharon co-founded Okapi in 2005 and is a Managing Director responsible for the life science investments in its first two funds and a Venture Partner in its third fund. Sharon was responsible for Okapi’s investment in Helixis (acq Nasdaq:ILMN), Focal Therapeutics (acq Nasdaq:HOLX), WellTok (acq: VirginPulse), Obalon Therapeutics (Nasdaq:OBLN, merged with Nasdaq:RSLS 2021), Orthalign, BioTrace, and WiserCare. She serves as a Director on the boards of Okapi portfolio companies WiserCare and BioTrace. She is also a Board Observer at OrthAlign.